Ligand Pharmaceutical Stock Earnings Reports

Ligand reported strong Q1 2026 operational momentum driven by its royalty-aggregation strategy. Total revenue was $52M (up 14% YoY) with royalty revenue of $43M (up 56% YoY) and adjusted EPS of $1.63 (up 23% YoY). Key commercial royalty drivers are Filspari (now Ligand's largest royalty following FDA approval in FSGS), Ohtuvayre, Qarziba and early contribution from Zelsuvmi. Palvella's QTORIN rapamycin delivered positive Phase III SELVA results for microcystic lymphatic malformations, creating a material mid-to-long-term opportunity. Ligand announced the pending acquisition of XOMA Royalty (expected close in Q3), which will add ~120 assets (7 marketed products, many late-stage programs and >100 earlier-stage assets). Management expects the XOMA deal to be immediately accretive (+$0.50 adjusted EPS in 2026 assuming Q3 close) and to add ~$1.50 adjusted EPS in 2027 from a full-year contribution, plus substantial operational synergies and tax attributes (NOLs and Section 174 credits). Liquidity entering the close: ~$780M cash/investments plus $200M undrawn revolver. 2026 guidance (assuming XOMA close): total revenue $270M–$310M, royalty revenue $225M–$250M, adjusted EPS $8.50–$9.50. Management reiterates a pure royalty aggregation model (shifted in 2022), continued deal activity (targeting several new investments per year), and expects strong long-term compounding revenue from the enlarged portfolio and multiple near-term catalysts (Filspari geographic/indication expansion, Palvella NDA submission, XOMA clinical and commercial milestones).